S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
Log in

Dynavax Technologies Stock Price, News & Analysis (NASDAQ:DVAX)

$4.21
+0.12 (+2.93 %)
(As of 10/15/2019 04:00 PM ET)
Today's Range
$3.99
Now: $4.21
$4.24
50-Day Range
$3.36
MA: $4.15
$4.91
52-Week Range
$2.60
Now: $4.21
$13.75
Volume791,287 shs
Average Volume1.35 million shs
Market Capitalization$274.30 million
P/E RatioN/A
Dividend YieldN/A
Beta0.46
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:DVAX
CUSIP26815810
Phone510-848-5100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.20 million
Book Value$1.01 per share

Profitability

Net Income$-158,900,000.00
Net Margins-781.10%

Miscellaneous

Employees249
Market Cap$274.30 million
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.


Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) released its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.03. The biopharmaceutical company earned $8.30 million during the quarter, compared to the consensus estimate of $8.24 million. Dynavax Technologies had a negative return on equity of 304.71% and a negative net margin of 781.10%. The firm's quarterly revenue was up 564.0% on a year-over-year basis. During the same period last year, the business posted ($0.63) earnings per share. View Dynavax Technologies' Earnings History.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Dynavax Technologies.

What price target have analysts set for DVAX?

4 brokerages have issued 1 year price objectives for Dynavax Technologies' shares. Their forecasts range from $13.00 to $30.00. On average, they anticipate Dynavax Technologies' stock price to reach $21.00 in the next year. This suggests a possible upside of 398.8% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

What is the consensus analysts' recommendation for Dynavax Technologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Has Dynavax Technologies been receiving favorable news coverage?

Media coverage about DVAX stock has trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Dynavax Technologies.

Who are some of Dynavax Technologies' key competitors?

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Micron Technology (MU).

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:
  • Mr. Eddie Gray, CEO & Director (Age 60)
  • Dr. Dennis A. Carson Ph.D., M.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 72)
  • Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 67)
  • Mr. David F. Novack, Sr. VP of Operations & Quality (Age 57)
  • Dr. Robert L. Coffman, Chief Scientific Officer & Sr. VP (Age 72)

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $4.21.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $274.30 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

What is Dynavax Technologies' official website?

The official website for Dynavax Technologies is http://www.dynavax.com/.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]


MarketBeat Community Rating for Dynavax Technologies (NASDAQ DVAX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  370 (Vote Outperform)
Underperform Votes:  375 (Vote Underperform)
Total Votes:  745
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel